Main Article Content
Hepatitis B virus infection (HBV) is still a major global health problem, which is an infectious disease that attacks the liver and a affects the lives of 325 million people worldwide and causing 1.4 million deaths a year. This study was designed to investigate and detection the levels of CXCL5 in the serum of hepatitis B virus (HBV) patients and risk group disease that infection patients (thalassemia, cancer and renal failure) by using enzyme-linked immunosorbent assay (ELISA) technique and compared level of CXCL5 among them and with the of normal level at Al-Najaf city. According to the best of our knowledge, this study is the first to display the levels of CXCL5 in different disease patients at al Najaf city. A total 155 sample were use in this study, that collection from different hospitals in Najaf city. The study design was included two experiments;The first was to indicated the HBV patients to ensure the infection of patients by HBV in additionally to take a history from each patient of risk groups disease for categorizing them into thalassemia, cancer, and renal failure patients’ groups. However, the second experiment detected the levels of CXCL5 in the HBV, thalassemia, cancer, and renal failure patients in different regions of Najaf City. The result showed that no significant between the levels of HBV (87.11 ± 2.87) and healthy (63.11 ± 11.66) groups, in additionally, the result showed the increased in the levels of CXCL5 in Renal Failure (140.4 ± 6.4) , Cancer (178.2 ± 6.8), and Thalassemia (118.9 ± 6.0). On conclusions, the present study confirmed the levels of CXCL5 is increased in the patients suffered HBV, cancer, renal failure and thalassemia in different levels among the healthy man.